SBIR/STTR Research Award
CHEMOTHERAPY OF LEISHMANIA WITH OLIQODEOXYNUCLEOTIDE PROBES
Award amount
$563,537Program and phase
SBIR · Phase IIAward year
1990Award details
- Awarding agency
- Department of Defense
- Branch
- Army
- Recipient company
- Epoch Pharmaceuticals, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
WE WILL INVESTIGATE THE ABILITY OF OLIGODEOXYNUCLEOTIDES COMPLEMENTARY TO THE SPLICED LEADER SEQUENCE OF LEISHMANIA ENRIETTII TUBULIN MRNA'S TO INHIT TRANSLATION AND TO KILL THE CELLS IN CULTURE. VARIOUS CHEMICAL MODIFICATIONS WILL BE MADE TO ENHANCE THE EFFECT OF THE OLIGOS. SUCCESSFUL AGENTS MAY BE VALUABLE, SELECTIVE CHEMOTHERAPEUTIC AGENTS AGAINST OTHER LEISHMANIA SPECIES IF MAD COMPLEMENTARY TO MRNA LEADERS FROM THOSE SPECIES.
Technology keywords
Not reported